A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer

Investigational New Drugs

Volumn 14, Issue 4, 1996, Pages 409-413

  Witte, Robert S ^a   Hsieh, Peggy ^b   Elson, Paul ^c   Oken, Martin M ^d   Trump, Donald L ^e  

^a GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d Virginia Piper Cancer Institute   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Amonifide; Caracemide; Homoharringtonine; Renal cell cancer

Indexed keywords

AMONAFIDE; CARACEMIDE; HOMOHARRINGTONINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LIVER TOXICITY; LUNG EMBOLISM; MALE; METABOLIC ACIDOSIS; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY FAILURE; SEPSIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; HARRINGTONINES; HUMANS; HYDROXYUREA; IMIDES; ISOQUINOLINES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NAPHTHALIMIDES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030465768     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00180819     Document Type: Article

References (31)

1. Harris DT: Hormonal therapy and chemotherapy of renal cell carcinoma. Seminars in Oncology 10(4):422-430, 1983
2. Hahn RG, Temkin NR, Sanlov RD, Perus C, Wampler GL, Horton J et al.: Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer. Cancer Treat Rep 62:1093-1095, 1978
3. Hahn RG, Bauer M, Wolter J, Creech R, Bennett JM, Wampler G: Phase II study of single agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer. Cancer Treat Rep 63:513-515, 1979
4. Hahn RG, Begg CB, Davis TE: Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer. Cancer Treat Rep 65:711-713, 1981
5. Earhart RH, Elson PJ, Rosenthal SN, Hahn RG, Slayton RE: Phase II study of PALA and AMSA in advanced renal cell carcinoma. Am J Clin Oncol 6:555-560, 1983
6. Elson PJ, Earhart RH, Kvols LK, Spigel R, Keller AM, Kias MS et al.: Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma. Cancer Treat Rep 71:331-332, 1987
7. Elson PJ, Kvols LK, Vogl SE, Glower DJ, Hahn RG, Trump DL et al.: Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivisin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma. Invest New Drugs 6:97-103, 1988
8. Trump DL, Elson PJ, Borden EC, Harris JE, Turtle RL, Whisnsnt JK et al.: High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Pilot Study. Cancer Treat Rep 71:165-169, 1987
9. Buzaid AC, Robertone A, Kisala, Salmon SE: Phase II study of interferon alfa-2a recombinant (Roferon-A) in metastatic renal cell carcinoma. J Clin Oncol 3:1083-1089, 1985
10. Creagan ET, Twito DI, Johansson SL, Schaid DJ, Johnson PS, Flaum MA et al.: A randomized prospective assessment of recombinant leukocyte A interferon with and without aspirin in advanced renal cell adenocarcinoma. J Clin Oncol 9:2104-2109, 1991
11. DeKernion JB, Sarna G, Figlin R, Linder A, Smith RB: The treatment of renal cell carcinoma with human leukocyte alpha interferon. J Urol 130:1063-1066, 1983
12. Muss HB, Constanzi JJ, Leavitt R, Williams RD, Kemf RA, Pollard R et al.: Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 5:286-291, 1987
13. Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU: Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3:1522-1528, 1985
14. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE: Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368-1375, 1993
15. Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI et al.: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 11:661-670, 1993
16. Dillman RO, Church C, Oldham RK, West WH, Schwartzberg L, Birch R: Inpatient continuous infusion interleukin-2 in 788 patients with cancer: the National Biotherapy Study Group experience. Cancer 71:2358-2370, 1993
17. Figlin RA, Belldegrun A, Moldawer N, Zeffren J, de Kernion J: Concomitant administration of recombinant interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 10:414-421, 1992
18. Minutes of the Phase I working group and the Biochemical Modulators Advising Group. A U.S. Government publication, 1986
19. National Cancer Institute Clinical Brochure. Caracemide (NSC 253272). August 1983
20. Raber MN, Adams F, Kavanagh J, Legha S, Dimery I, Krakoff I: Phase I trial of caracemide using bolus and infusional schedules. Cancer Treat Rep 71:349-352, 1987
21. Clinical Brochure: Homoharringtonine (NSC 141633) (IND 19125), IDB, CTEP, DCT, NCI, Bethesda, MD, August 1982
22. Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ: Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 63:813-817, 1989
23. Stewart JA, Cassileth PA, Bennett JM, O'Connell MJ: Continuous infusion homoharringtonine (NSC 141633) in refractory acute non-lymphocytic leukemia. An ECOG pilot study. Am J Clin Oncol 11:627-629, 1988
24. Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, Cook P, Baskind P: Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 6:1185-1188, 1992
25. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
26. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:347-481, 1958
27. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Research 48:7310-7313, 1988
28. Feun LJ, Savaraj N, Landy H, Levin H, Lampidis T: Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors. J Neurooncol 9:159-163, 1990
29. Runge-Morris MA, Kies MS, Yokes E, Blough R, Weidner L, Knop R, Rowland K: Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council study. Invest New Drugs 7:269-273, 1989
30. Lad T, Schor J, Mullane M, Carroll R, Chernicoff D, Blough R, Weidner L: Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study. Invest New Drugs 10:27-28, 1992
31. Belani CP, Eisenberger M, Van Echo D, Hiponia D, Aisner J: Phase II study of caracemide in advanced or recurrent non-small cell lung cancer. Cancer Treat Rep 71:1099-1100, 1987